Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03902522 · ClinicalTrials.gov registry record · Phase 2
PRO 140 in Treatment-Experienced HIV-1 Subjects
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03902522 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 6 participants.
The verdict
NCT03902522, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.
Interventions
- DRUG PRO 140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2020-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03902522
The ClinicalTrials.gov registry entry for NCT03902522 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRO 140 is the first listed.
NCT03902522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03902522 about?
NCT03902522 is a clinical study titled "PRO 140 in Treatment-Experienced HIV-1 Subjects". The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-...
What is the current status of trial NCT03902522?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-06-25. Estimated completion is 2020-05-18.
What interventions are being tested in trial NCT03902522?
The interventions under investigation include: PRO 140 (DRUG).
Who is sponsoring clinical trial NCT03902522?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.